BlackRock Inc. bought a new stake in Denali Therapeutics Inc. (NASDAQ: DNLI) in the undefined quarte

B. Riley Securities analyst Mayank Mamtani maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy

Denali's Avlayah launch drives strong uptake and a 33.1% three-month stock gain, but regulatory and

AVLAYAH's approval has helped validate Denali Therapeutics' TransportVehicle platform. They're now m

Denali Therapeutics (NASDAQ: DNLI - Get Free Report) and Humacyte (NASDAQ: HUMA - Get Free Report) a

Denali Therapeutics (DNLI) is transitioning from a neuroscience platform to a commercial biotech wit

On June 30, 2026, Baillie Gifford (Trades, Portfolio) executed a reduction of 106,249 shares in Dena

California State Teachers Retirement System increased its position in shares of Denali Therapeutics

UBS analyst Michael Yee maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the pri

Denali Therapeutics narrows Q2 loss as Avlayah sales top estimates, with strong launch traction and

Denali Therapeutics Inc. (DNLI) Q2 2026 Earnings Call Transcript

Denali Therapeutics NASDAQ: DNLI reported $3.6 million in net product revenue from AVLAYAH during th

Denali Therapeutics Inc. (DNLI) came out with a quarterly loss of $0.68 per share versus the Zacks C

Denali Therapeutics (NASDAQ:DNLI) reported quarterly losses of $(0.68) per share which missed the an

Strong first full quarter of AVLAYAH™ (tividenofusp alfa-eknm) launch generated $3.6 million in net

SOUTH SAN FRANCISCO, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNL

Morgan Stanley analyst Matthew Harrison maintains Denali Therapeutics (NASDAQ:DNLI) with a Overwe

Deutsche Bank analyst David Hoang maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and rais

Denali Therapeutics gains FDA approval for Avlayah, but pipeline setbacks and partner exits raise fr

JP Morgan analyst Jessica Fye reinstates Denali Therapeutics (NASDAQ:DNLI) with a Overweight and

SOUTH SAN FRANCISCO, Calif., July 09, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNL

Denali Therapeutics surges on Avlayah???s FDA approval, PRV sale and pipeline progress, but partners

DNLI will gain $195M from selling its Rare Pediatric Disease PRV, adding non-dilutive capital to adv

Denali Therapeutics Inc. (Nasdaq: DNLI) today announced it has entered into a definitive agreement t

SOUTH SAN FRANCISCO, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNL

Denali Therapeutics Inc. (DNLI) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Denali Therapeutics (DNLI) maintains a "Strong Buy" rating following FDA Accelerated Approval of AVL

Morgan Stanley analyst Matthew Harrison maintains Denali Therapeutics (NASDAQ:DNLI) with a Overwe

The Phase 2b LUMA study of BIIB122 in early-stage Parkinson's disease did not meet its primary o

Morgan Stanley analyst Matthew Harrison maintains Denali Therapeutics (NASDAQ:DNLI) with a Overwe

BTIG analyst Thomas Shrader reiterates Denali Therapeutics (NASDAQ:DNLI) with a Buy and maintains

Wedbush analyst Laura Chico maintains Denali Therapeutics (NASDAQ:DNLI) with a Outperform and low

Denali Therapeutics (NASDAQ:DNLI) reported quarterly losses of $(0.69) per share which beat the anal

Nancy Pelosi Stock Tracker highlighted Claude AI's Denali Therapeutics earnings bet, which targe

Top Wall Street analysts changed their outlook on top names. See all analyst rating changes, includi

Baird analyst Joel Beatty maintains Denali Therapeutics (NASDAQ:DNLI) with a Outperform and raise

Denali shares fall after Takeda exits DNL593 deal; company regains full rights and targets Phase 1/2

Denali plans to continue clinical development of DNL593, which is designed to deliver progranulin to

Item 7.01    Regulation FD Disclosure. Royalty Agreement Closing and Funding On March 27, 2026, the

Morgan Stanley analyst Matthew Harrison maintains Denali Therapeutics (NASDAQ:DNLI) with a Overwe

Goldman Sachs analyst Salveen Richter maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and

Stifel analyst Paul Mattels maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the

Wall Street analysts change ratings on top stocks: BNP Paribas cuts Chewy Inc, Bernstein cuts Qualco

Denali Therapeutic snags FDA accelerated approval for Avlayah for Hunter syndrome, analyst flags str

Baird analyst Joel Beatty maintains Denali Therapeutics (NASDAQ:DNLI) with a Outperform and raise

HC Wainwright & Co. analyst Andrew S. Fein maintains Denali Therapeutics (NASDAQ:DNLI) with a

https://www.fda.gov/news-events/press-announcements/fda-approves-drug-treat-neurologic-manifestation

US stocks tumble as Dow falls 650 points. Relmada Therapeutics stock rises 40.8% on promising cancer

BTIG analyst Thomas Shrader maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the

Denali Therapeutics (NASDAQ:DNLI) reported quarterly losses of $(0.73) per share which beat the anal